Home > Healthcare > Anti-retroviral Drugs Market

Anti-retroviral Drugs Market – By Product (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, NRTIs, NNRTIs), Type (Branded, Generic), Age Group, Distribution Channel - Global Forecast, 2024 – 2032

  • Report ID: GMI8298
  • Published Date: Feb 2024
  • Report Format: PDF

Anti-retroviral Drugs Market Size

Anti-Retroviral Drugs Market size was valued at USD 29.1 billion in 2023 and is anticipated to register of over 4.2% CAGR from 2024 to 2032. This growth trajectory is propelled by several factors, including increased investment in research and development, the emergence of multiple generic drug alternatives, and the advent of novel drugs boasting enhanced efficacy.

Anti-Retroviral Drugs Market

Furthermore, the mounting prevalence of HIV and the broader availability of combination anti-retroviral therapy (cART) are substantial drivers of market expansion. For instance, in July 2022, the World Health Organization (WHO) reported that around 38.4 million individuals were living with HIV globally in 2021. This uptrend in HIV cases is expected to bolster the demand for both anti-retroviral and anti-viral drugs, highlighting the crucial need for effective treatments to address the growing prevalence of the virus.

Antiretroviral drugs (ARVs) are medications used to treat infections caused by retroviruses, particularly the human immunodeficiency virus (HIV). These drugs work by targeting different stages of the HIV replication cycle, helping to suppress viral replication, reduce the viral load in the body, and slow down the progression of HIV infection to acquired immunodeficiency syndrome (AIDS).

Anti-retroviral Drugs Market Trends

  • The market is expanding owing to new drug approvals and product launches. For instance, in December 2021, the U.S. FDA authorized Apretude used as pre-exposure prophylaxis (PrEP) to lower the risk of HIV infection acquired via sexual activity in adults and adolescents who are at-risk. Therefore, such approvals and new drug launches are impelling the growth of the market.


  • Furthermore, pharmaceutical companies investing in research and development to create more effective and tolerable anti-retroviral drugs is propelling the market growth. This includes developing new formulations, combination therapies, and long-acting drugs to improve patient adherence and outcomes. Thus, aforementioned factors are anticipated to accelerate the market expansion.

Anti-retroviral Drugs Market Analysis

Anti-retroviral Drugs Market, By Product, 2021 – 2032 (USD Billion)

Based on the product, the market is classified into protease inhibitors, integrase inhibitors, multi-class combination products, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and other drug classes. The multi-class combination products dominated the market with revenue of USD 7.9 billion in 2023.

  • The segment growth is majorly attributable to the growing burden of HIV and new drug approvals. Additionally, several market players are focusing on development of breakthrough products to maintain their competitive edge and expand in new regional markets.
  • Furthermore, the growing number of HIV cases worldwide and the efficiency of multiclass combination product medications for its treatment is raising the demand for these drugs, thus driving the segmental growth. For instance, an article published in the journal Nanomaterials in February 2021 described the remarkable outcomes of using multiclass combination product therapy to reduce HIV symptoms. Thus, demand for multiclass combination product is anticipated to impel in the market.
Anti-retroviral Drugs Market, By Type (2023)

Based on type, the anti-retroviral drugs market is classified into branded and generic. The branded segment held the highest business share of 67.2% in 2023.

  • The segment is expected to witness significant growth in the forecast period owing to ongoing advancements and innovation in the development, distribution, and utilization of branded antiretroviral drugs, with a focus on improving treatment efficacy, accessibility, and patient outcomes in the management of HIV/AIDS.
  • Further, the segment's dominance is attributed to widespread use of branded drugs due to their established efficacy, safety profile, and increasing endorsement by healthcare authorities. Adding to this, prominent market competitors are working on creating novel therapies to prevent the transmission of infection.

Based on age group, the anti-retroviral drugs market is classified into adult, pediatric, and geriatric. The adult segment is expected to hold the highest revenue throughout the forecast period.

  • There is increasing recognition of the importance of early initiation of antiretroviral therapy (ART) in adults diagnosed with HIV infection. Initiating ART early, regardless of CD4 cell count, leads to improved clinical outcomes, reduced HIV transmission risk, and decreased morbidity and mortality.
  • Therefore, increasing need for HIV diagnostics among adult population is anticipated to contribute significantly to the market growth

Based on distribution channel, the anti-retroviral drugs market is classified into hospital pharmacy, retail pharmacy, online pharmacy. The hospital pharmacy segment held the highest business share of 43.1% in 2023.

  • The rising geriatric population, increasing HIV cases, and the increasing number of hospitalizations are the key factors driving the segment expansion.
  • Further, hospital pharmacies are increasingly integrating HIV services within their facilities, offering comprehensive care for patients living with HIV/AIDS. This integration includes providing antiretroviral therapy (ART), medication management, adherence support, and monitoring of treatment outcomes. Thus, adoption of technologically advanced solutions and employment of specialized HIV pharmacists is anticipated to accelerate the segment progress.
North America Anti-retroviral Drugs Market, 2020 – 2032 (USD Billion)

In 2023, North America secured a substantial market share in the global anti-retroviral drugs market and is expected to dominate throughout the forecast period.

  • The factors such as the increasing number of HIV cases, presence of prominent competitors, drug approvals and product launches in the region and technological improvements in drug development will contribute significantly to the market's growth over the projection period.
  • For instance, according to the World Health Organization in 2022, around 39 million people were living with HIV globally. Thus, a large number of people living with HIV, as well as the increasing prevalence of HIV, are driving demand for anti-retroviral treatments, resulting in the rise of the market in the region.

Anti-retroviral Drugs Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective anti-retroviral drugs.

Anti-retroviral Drugs Market Companies

Prominent players operating in the anti-retroviral drugs industry are as mentioned below:

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson and Johnson
  • Merck & Co, Inc.
  • Pfizer Inc.
  • Viatris Inc.

Anti-retroviral Drugs Industry News

  • In August 2022, Gilead received global regulatory approval for Sunlenca (Lenacapavir), a twice-yearly HIV treatment option. This approval was granted by the European Commission, making Sunlenca the only twice-yearly HIV treatment option available. The Sunlenca is used in combination with other antiretroviral drugs in adults with multi-drug resistant HIV. Therefore, the launch of this drug helped company to address a critical unmet clinical need.
  • In September 2022, Merck announced the initiation of a new Phase 3 clinical trial to evaluate the efficacy and safety of once-daily oral islatravir for the treatment of HIV-1 infection. The trial will involve a lower dose of islatravir in combination with doravirine and will enrol previously untreated individuals as well as those who have already received treatment. The development of this drug is anticipated to enhance company’s overall capability in HIV treatment and strengthen its market position.

The anti-retroviral drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

  • Protease inhibitors
  • Integrase inhibitors
  • Multi-class combination products
  • Nucleoside reverse transcriptase inhibitors (NRTIs)
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Other drug classes

Market, By Type

  • Branded
  • Generic

Market, By Age Group

  • Adult
  • Pediatric
  • Geriatric

Market, By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Anti-retroviral drugs market size was USD 29.1 billion in 2023 and is expected to register 4.2% CAGR from 2024-2032 owing to the increased investment in research and development, and the emergence of multiple generic drug alternatives worldwide.

The multi-class combination segment reached USD 7.9 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to the growing burden of HIV and new drug approvals.

Anti-retroviral drugs market from the branded segment held 67.2% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to ongoing advancements and innovation in the development, distribution, and utilization of branded antiretroviral drugs.

AbbVie Inc., Bristol-Myers Squibb Company, Cipla, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc., Johnson and Johnson, Merck & Co, Inc., Pfizer Inc., and Viatris Inc., are some of the major anti-retroviral drugs companies worldwide.

Anti-retroviral Drugs Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 257
  • Countries covered: 20
  • Pages: 160
 Download Free Sample